Hangzhou Qihan Biotech Co., Ltd.

About Hangzhou Qihan Biotech Co., Ltd.

Qihan Biotech is a biotechnology company focused on using multiplexable genome editing and transplantation immunology to develop immunologically privileged allogeneic cells and xenogeneic organs as therapies for cancer, organ failure, and other medical conditions. Their vision is to make cell and organ therapies universally available to patients.

Products & Services

QN-019a:A multi-locus gene-editing cell therapy product for treating CD19-positive B-Cell Lymphoma, approved for clinical trials by the National Medical Products Administration (NMPA).

Cell and Organ Therapies:Therapies utilizing multiplexable genome editing to create immunologically privileged allogeneic cells and xenogeneic organs for treating various medical conditions.

Specialties

Multiplexable Gene Editing Genome Editing for Immune-Privileged Features Transplantation Immunology Cell Therapy Organ Therapy

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Pre-Series B T: - FT: Pre-Series B	A: 16000000 MR: - FA: exceeding $16 million FAN: 16000000	D: 2023-09-22 FD: 2023-09-22	1 investors

Pre-Series B Latest

2023-09-22

$16.0M

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

S

Steven Holtzman

L

Luhan Yang

L

Lynn Yang

K

Kexiang Zhou

T

Tony W. Ho

M.D.

N

Naxin Yao

View 13 more team members with Pro

Unlock Full Team Directory

Recent News